Galantamine: use in Alzheimer's disease and related disorders (Q36107053)

12 August 2017

1 reference

title

Galantamine: use in Alzheimer's disease and related disorders (English)

1 reference

12 August 2017

0 references

Roger Bullock

1

1 reference

12 August 2017

publication date

1 March 2004

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

12 August 2017

published in

1 reference

12 August 2017

volume

4

1 reference

12 August 2017

issue

2

1 reference

12 August 2017

page(s)

153-163

1 reference

Survival in Alzheimer's disease and vascular dementias.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Cognitive impairment in elderly people: population based estimate of the future in England, Scotland, and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Galanthamine: pharmacokinetics, tissue distribution and cholinesterase inhibition in brain of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Neuronal nicotinic receptors in the human brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Change in nicotinic receptor subtypes in temporal cortex of Alzheimer brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease--a stereological approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Mecamylamine interactions with galantamine and donepezil: effects on learning, acetylcholinesterase, and nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

The effects of donepezil in Alzheimer's disease - results from a multinational trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Caregiver time use: An outcome measure in clinical trial research on Alzheimer's disease*

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Apolipoprotein E genotype and gender influence response to tacrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Use of galantamine to treat vascular dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Incidence of stroke in relation to cognitive function and dementia in the Kungsholmen Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

Adjuvant galantamine administration improves negative symptoms in a patient with treatment-refractory schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.4.2.153

21 January 2018

Identifiers

DOI

10.1586/14737175.4.2.153

1 reference

12 August 2017

1 reference